13D Filings -- Barron's
Piper Sandler Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $93
Form 144 | Soleno Therapeutics(SLNO.US) Insider Proposes to Sell 51.42 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Oct 21, $Soleno Therapeutics(SLNO.US)$ Insider Abingworth Bioventures VII LP intends to sell 949.34K shares of its common stock on Oct 21, with a total market value of
Express News | Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.d.
Press Release: Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D.
TriMas, Soleno Therapeutics, Ring Energy, and More Stocks See Action From Activist Investors -- Barrons.com
Soleno Therapeutics (SLNO): Breakthroughs in Prader-Willi Syndrome Treatment
Express News | Carlyle Group Reports 8.1% Stake in Soleno Therapeutics as of Oct 8 Vs 9.9% as of Sept 6- SEC Filing
SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA
A Quick Look at Today's Ratings for Soleno Therapeutics(SLNO.US), With a Forecast Between $65 to $75
Why Soleno Therapeutics Stock Blasted 9% Higher Today
PepsiCo, DocuSign, Robinhood And Other Big Stocks Moving Higher On Tuesday
Soleno Therapeutics Update on DCCR 'a Positive Surprise,' Says Stifel
Soleno Stock Rises as NDA for Lead Asset Doesn't Need FDA Advisory Meeting
Soleno Therapeutics Announces FDA Review Division Determined That There Does Not Appear To Be A Need For An Advisory Committee Meeting At This Time For The NDA For DCCR Extended-Release Tablets For The Treatment Of Prader-Willi Syndrome
Express News | Soleno Therapeutics Inc - FDA: No Advisory Committee Meeting Needed for Dccr Nda
Express News | Soleno Therapeutics Announces Regulatory Update on Dccr (Diazoxide Choline) Extended-Release Tablets to Treat Prader-Willi Syndrome
Form 144 | Soleno Therapeutics(SLNO.US) Insider Proposes to Sell 125.2 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Oct 7, $Soleno Therapeutics(SLNO.US)$ Insider Abingworth Bioventures VII LP intends to sell 2.52 million shares of its common stock on Oct 7, with a total market value of
Stifel Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $74
Soleno Therapeutics Insider Sold Shares Worth $1,069,306, According to a Recent SEC Filing